EUPRAXIA PHARMACEUTICALS INC.

Non-clinical Studies

We have completed multiplenon-clinical investigations with EP-104IAR, including a large IND-enabling non-clinical study in dogs. Non-clinical data have indicated that after a single high-dose IA injection of EP-104IAR to the knees of dogs, FP was released locally for greater than ten months with moderate exposure in the plasma. There was no evidence of cartilage damage in dogs over theten-month follow-up period at any of the administered doses. In this study, a low dose of EP-104IAR released FP locally for longer than eight months with minimal systemic exposure. This dose was used to justify the dose selection in our Phase 2 clinical trial. Both U.S. and European competent authorities have reviewed ournon-clinical safety data and deemed this information suitable to support clinical research studies.

Severalnon-clinical studies are underway to support the Phase 3 and registration program. These activities include safety and biocompatibility evaluations of EP-104IAR excipients as well asnon-clinical studies to provide information needed to support the continued clinical investigation of EP-104IAR product candidates in humans.